Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Quest Diagnostics is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-10-06Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- 10-Q2026-07-23Quarterly report
- 8-K2026-07-23Current report (material event)
- 11-K2026-06-1811-K
- 8-K2026-05-21Current report (material event)
- 8-K2026-05-08Current report (material event)
- 8-K2026-05-01Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- 424B22026-04-28424B2
- FWP2026-04-27FWP
- 424B22026-04-27424B2
- 10-Q2026-04-22Quarterly report
- 8-K2026-04-21Current report (material event)
- DEFA14A2026-04-06DEFA14A
- DEF 14A2026-04-06Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-12Current report (material event)
- 10-K2026-02-26Annual report
- 8-K2026-02-10Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-10-21Current report (material event)
- 10-Q2025-10-21Quarterly report
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- 10-Q2025-07-23Quarterly report
- 8-K2025-07-22Current report (material event)
- 11-K2025-06-2011-K
- S-3ASR2025-06-20S-3ASR
- 8-K2025-05-22Current report (material event)
- SCHEDULE 13G2025-05-14SCHEDULE 13G
- 10-Q2025-04-23Quarterly report
- 8-K2025-04-22Current report (material event)
- SCHEDULE 13G/A2025-04-17SCHEDULE 13G/A
- DEFA14A2025-04-11DEFA14A
- DEFA14A2025-04-04DEFA14A
- DEF 14A2025-04-04Proxy statement
- 8-K2025-03-19Current report (material event)
- 8-K2025-03-19Current report (material event)
- 10-K2025-02-20Annual report
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.